Albumin Sales to Drive $700 Million Growth in Major Critical Care Market, Says the New Study on ASDReports

Monday 6 October 2014, Amsterdam

The critical care market across eight major countries (the US, UK, France, Germany, Italy, Spain, Japan and Canada) was worth an estimated $1.8 billion in 2013 and will grow to $2.5 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 4.7%, according to the new study, now available on ASDReports.

The new report states that the majority of revenue will continue to be generated by albumin sales, which will rise from $1.1 billion in 2013 to $1.6 billion by 2020. Albumin was used to treat the highest share of the critical care patient population across all eight markets in 2013, with 2.2 million patients out of a total 2.4 million.

Vijaya Vulapalli, Analyst for the new report, says: “Albumin, which accounts for around 60% of total human plasma mass, is fundamental to the maintenance of blood volume and the stability of blood circulation. It plays a vital role in the management of many clinically significant, high-risk conditions, such as cardiopulmonary bypass surgery, burn cases and acute liver failure.

“Albumin can also be used in the emergency treatment of shock and in other similar conditions where blood volume needs to be restored urgently.”

The new report forecasts that albumin demand will increase at a CAGR of 15–20% over the next few years, and the approval of additional indications, such as treatment for Alzheimer’s disease, could contribute towards this growth.

However, Vulapalli is cautious about overstating the usefulness of human albumin for volume replacement or the correction of hypoalbuminemia.

The analyst explains: “The theoretical and pharmacological value of the use of human albumin has not yet been shown to have a major role to play in clinical settings. With some exceptions, such as the administration of albumin to women in early pregnancy, there appear to be very few indications for which studies have supported its use.”